



15. Rice J, Cameron M. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. *Curr Neurol Neurosci Rep* 2018; 18(8): 50.
16. SÚKL. SPC Tecfidera. [https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
17. SÚKL. SPC Gilenya. [https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
18. SÚKL. SPC Mavenclad. [https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
19. SÚKL. SPC Mayzent. [https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
20. SÚKL. SPC Aubagio. [https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
21. SÚKL. SPC Avonex. [https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
22. SÚKL. SPC Rebif. [https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
23. SÚKL. SPC Betaferon. [https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
24. SÚKL. SPC Plegridy. [https://www.ema.europa.eu/en/documents/product-information/plegridy-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/plegridy-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
25. SÚKL. SPC Copaxone. <https://www.sukl.cz/modules/medication/download.php?file=SPC162779.pdf&type=spc&as=copaxone-spc> (přístup 14. 3. 2021).
26. SÚKL. SPC Lemtrada. [https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
27. SÚKL. SPC Tysabri. [https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
28. SÚKL. SPC Ocrevus. [https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_cs.pdf) (přístup 14. 3. 2021).

Cannabinoids for Treatment of MS Symptoms: State of the Evidence. *Curr Neurol Neurosci Rep* 2018; 18(8): 50.

16. SÚKL. SPC Tecfidera. [https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
17. SÚKL. SPC Gilenya. [https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
18. SÚKL. SPC Mavenclad. [https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
19. SÚKL. SPC Mayzent. [https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
20. SÚKL. SPC Aubagio. [https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
21. SÚKL. SPC Avonex. [https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
22. SÚKL. SPC Rebif. [https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
23. SÚKL. SPC Betaferon. [https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
24. SÚKL. SPC Plegridy. [https://www.ema.europa.eu/en/documents/product-information/plegridy-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/plegridy-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
25. SÚKL. SPC Copaxone. <https://www.sukl.cz/modules/medication/download.php?file=SPC162779.pdf&type=spc&as=copaxone-spc> (přístup 14. 3. 2021).
26. SÚKL. SPC Lemtrada. [https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
27. SÚKL. SPC Tysabri. [https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_cs.pdf) (přístup 14. 3. 2021).
28. SÚKL. SPC Ocrevus. [https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_cs.pdf) (přístup 14. 3. 2021).